Helminthic Diseases: Onchocerciasis and Loiasis

International Encyclopedia of Public Health

Volumn , Issue , 2016, Pages 576-587

  Remme, Jan H F ^a   Boatin, Boakye ^a   Boussinesq, Michel ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Africa; Blackfly; Community directed treatment; Cost effectiveness; Encephalopathy; Ivermectin; Larvicide; Latin America; Loa loa; Macrofilaricide; Microfilaricide; Onchocerca volvulus; Onchocerciasis; Onchodermatitis; River blindness; Simulium; Vector control

Indexed keywords

EID: 85026759028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-803678-5.00206-X     Document Type: Chapter

References (37)

1. + T cells from microfilaraemic subjects compared with amicrofilaraemics. Clin. Exp. Immunol. 1997, 108:272-278.
2. Boussinesq M., Gardon J., Gardon-Wendel N., Chippaux J.P. Clinical picture epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2003, 2(Suppl. 1):S4.
3. Brieger W.R., Awedoba A.K., Eneanya C.I., et al. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop. Med. Int. Health 1998, 3:951-961.
4. Coffeng L.E., Stolk W.A., Zoure H.G., et al. African Programme for Onchocerciasis Control 1995-2015: model-estimated health impact and cost. PLoS Negl. Trop. Dis. 2013, 7(1):e2032.
5. Crosskey R.W. The Natural History of Blackflies 1990, Wiley, Chichester, UK.
6. Dadzie K.Y., Remme J., Rolland A., Thylefors B. The effect of 7-8years of vector control on the evolution of ocular onchocerciasis in West African savanna. Trop. Med. Parasitol. 1986, 37:263-270.
7. Duke B.O.L. Studies on loiasis in monkeys IV: experimental hybridization of the human and simian strains of Loa. Ann. Trop. Med. Parasitol. 1964, 58:390-408.
8. Guillet P., Seketeli A., Alley E., et al. Impact of combined large-scale ivermectin distribution and vector control on transmission of Onchocerca volvulus in the Niger basin, Guinea. Bull. W.H.O. 1995, 73:199-205.
9. Gustavsen K., Hopkins A., Sauerbrey M. Onchocerciasis in the Americas: from arrival to (near) elimination. Parasit. Vectors 2011, 4:205.
10. Kaiser C., Pion S.D., Boussinesq M. Case-control studies on the relationship between onchocerciasis and epilepsy: systematic review and meta-analysis. PLoS Negl. Trop. Dis. 2013, 7(3):e2147.
11. Klion A.D., Massougbodji A., Horton J., et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J. Infect. Dis. 1993, 168:202-206.
12. Murdoch M.E., Asuzu M.C., Hagan M., et al. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann. Trop. Med. Parasitol. 2002, 96:283-296.
13. Plaisier A.P., Van Oortmarssen G.J., Remme J., Habbema J.D. The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Tropica 1991, 48:271-284.
14. Remme J.H.F., Feenstra P., Lever P.R., et al. Tropical diseases targeted for elimination: chagas disease, lymphatic filariasis, onchocerciasis and leprosy. Disease Control Priorities in Developing Countries 2006, Oxford University Press, New York. second ed. T. Jamison, J.G. Breman, A.R. Measham (Eds.).
15. Saint Andre A., Blackwell N.M., Hall L.R., et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002, 295:1892-1895.
16. Takougang I., Meremikwu M., Wandji S., et al. Rapid assessment method for prevalence and intensity of Loa loa infection. Bull. W.H.O. 2002, 80:852-858.
17. Tielsch J.M., Beeche A. Impact of ivermectin on illness and disability associated with onchocerciasis. Trop. Med. Int. Health 2004, 9:A45-A56.
18. Traore M.O., Sarr M.D., Badji A., et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl. Trop. Dis. 2012, 6(9):e1825.
19. Winnen M., Plaisier A.P., Alley E.S., et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa?. Bull. W.H.O. 2002, 80(5):384-391.
20. Zimmerman P.A., Dadzie K.Y., De Sole G., Remme J., Alley E.S., Unnasch T.R. Onchocerca volvulus DNA probe classification correlates with epidemiologic patterns of blindness. J. Infect. Dis. 1992, 165:964-968.
21. Zouré H.G.M., Wanji S., Noma M., et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl. Trop. Dis. 2011, 5(6):e1210.
22. Zouré H.G., Noma M., Tekle A.H., et al. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected. Parasit. Vectors 2014, 7:326.
23. Amazigo U.V., Obono M., Dadzie K.Y., et al. Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC). Ann. Trop. Med. Parasitol. 2002, 96(Suppl. 1):S75-S92.
24. Boatin B.A., Richards F.O. Control of onchocerciasis. Adv. Parasitol. 2006, 61:349-394.
25. Boussinesq M. Loiasis. Ann. Trop. Med. Parasitol. 2006, 100:715-731.
26. Dadzie Y., Neira M., Hopkins D. Final report of the conference on the eradicability of Onchocerciasis. Filaria J. 2003, 2:2.
27. Hodgkin C., Molyneux D.H., Abiose A., et al. The future of onchocerciasis control in Africa. PLoS Negl. Trop. Dis. 2007, 1(1):e74.
28. Homeida M., Braide E., Elhassan E., et al. APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. Ann. Trop. Med. Parasitol. 2002, 96:93-104.
29. Klion A.D., Massougbodji A., Sadeler B.C., Ottesen E.A., Nutman T.B. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J. Infect. Dis. 1991, 163:1318-1325.
30. The Importance of Onchocercal Skin Disease: Report of a Multi-country Study 1995, Pan African Study Group on Onchocercal Skin Disease, World Health Organization, Geneva, Switzerland.
31. Pinder M. Loa loa - a neglected filaria. Parasitol. Today 1988, 4:279-284.
32. Remme J.H. Research for control: the onchocerciasis experience. Trop. Med. Int. Health 2004, 9:243-254.
33. Richards F.O., Boatin B., Sauerbrey M., Seketeli A. Control of onchocerciasis today: status and challenges. Trends Parasitol. 2001, 17:558-563.
34. Toure F.S., Kassambara L., Williams T., et al. Human occult loiasis: improvement in diagnostic sensitivity by the use of a nested polymerase chain reaction. Am. J. Trop. Med. Hyg. 1998, 59:144-149.
35. Wahl G., Georges A.J. Current knowledge on the epidemiology diagnosis, immunology, and treatment of loiasis. Trop. Med. Parasitol. 1995, 46:287-291.
36. Onchocerciasis and its control: report of a WHO Expert Committee on Onchocerciasis Control. W.H.O. Tech. Rep. Ser. 1995, 852:1-104. WHO.
37. - Mectizan Donation Program (MDP). http://www.mectizan.org/loarecs.asp.